Delivery Order SPE2DB22D3009-SPE2DB25FBD78
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order on August 1, 2025, by the Defense Logistics Agency's Medical Supply Chain to provide Ondansetron ODT 4 mg tablets (30-count) with a firm fixed price ceiling value of $5,173.92. The order is scheduled for completion by August 4, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This non-set-aside award represents a routine pharmaceutical procurement supporting federal medical supply needs, consistent with...
- AmerisourceBergen Drug Corp received a competitively awarded delivery order from the Defense Logistics Agency's Medical Supply Chain for Ondansetron ODT 4 mg tablets (30-count units) valued at $31,190.34. The contract was awarded on September 18, 2025, with an ultimate completion date of September 19, 2025, and carries firm fixed pricing with no set-aside designation. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this delivery order,...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on April 24, 2025, for the supply of Ondansetron ODT 4 mg tablets in a 30-count package. This contract, valued at $20,565.05, represents a firm fixed-price delivery order with an ultimate completion date of April 25, 2025. The award was made on a competitive basis without any set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania—which serves as the place of...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 12, 2025, for the supply of Ondansetron ODT 4 mg tablets in a 30-count package. This is a firm fixed-price, non-set-aside contract with a ceiling value of $5,923.61 and an ultimate completion date of September 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order contract by the Defense Logistics Agency for Ondansetron ODT 4 mg tablets (30-count supply) valued at $4,396.53 with a firm fixed price structure. The award was made on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside competitive award is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency's Medical Supply Chain for Ondansetron ODT 4mg tablets (30-count supply) valued at $48,173.20. The contract award, issued on August 25, 2025, with an ultimate completion date of September 22, 2025, utilizes firm fixed pricing with no set-aside designation. This delivery order represents a competitively awarded transaction under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count) with a ceiling value of $1,254.19 on August 4, 2025. This firm fixed-price delivery order, which is scheduled for completion by August 5, 2025, represents a non-competitive set-aside award under AmerisourceBergen's existing contract vehicle with DLA. The pharmaceutical distributor will perform the work at its corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $18,470.50 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count packaging). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine...
- The Defense Logistics Agency awarded a $1,293.48 firm fixed price delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count) with a completion date of September 19, 2025. This competitively awarded, non-set-aside contract represents a single delivery order against AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $28,723.39 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This firm fixed-price delivery order, issued on August 18, 2025, with an ultimate completion date of August 19, 2025, represents a non-competitive award to the pharmaceutical distributor. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is part of...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB25FBD78Delivery Order
AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for Ondansetron ODT 4 mg tablets (30-count) valued at $4,536.73 under a firm fixed-price contract type. The award was made on August 22, 2025, with an ultimate completion date of August 25, 2025. This is a non-set-aside award, indicating it was competitively awarded. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a small transaction within AmerisourceBergen's significantly larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a prime pharmaceutical vendor for the Defense Logistics Agency's medical supply chain, AmerisourceBergen supplies a comprehensive portfolio of medications and medical supplies to support military healthcare systems and other federal healthcare customers. The company's role as a critical vendor reflects its capability to fulfill federal pharmaceutical procurement requirements across multiple therapeutic domains and geographic regions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 8/22/25 |